Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

AZD1222 effectiveness against severe COVID-19 in individuals with comorbidity or frailty: The RAVEN cohort study

Meeraus W. et al, (2024), Journal of Infection, 88

Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes

Hayward G. et al, (2024), Journal of Infection, 88

Estimating Vitamin K Antagonist Anticoagulation Benefit in People With Atrial Fibrillation Accounting for Competing Risks: Evidence From 12 Randomized Trials.

Shah SJ. et al, (2024), Circ Cardiovasc Qual Outcomes

Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial.

Hobbs FDR. et al, (2024), Infect Dis Ther, 13, 521 - 533

The feasibility of population screening for paroxysmal atrial fibrillation using handheld ECGs.

Mant J. et al, (2024), Europace

Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients

Standing JF. et al, (2024), Nature communications, 15

Risk of severe COVID-19 outcomes after autumn 2022 COVID-19 booster vaccinations: a pooled analysis of national prospective cohort studies involving 7.4 million adults in England, Northern Ireland, Scotland and Wales

Bedston S. et al, (2024), The Lancet Regional Health - Europe, 37

Disparities in COVID-19 Mortality Amongst the Immunosuppressed: A Systematic Review and Meta-analysis for Enhanced Disease Surveillance.

Leston M. et al, (2024), J Infect

Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of adverse outcomes in the UK PANORAMIC trial.

Png ME. et al, (2024), Br J Gen Pract

Protocol for an e-Delphi study to achieve consensus on a definitive adult immunosuppressed phenotype (Preprint)

Leston M. et al, (2024)

Diagnostic accuracy of a point-of-care antigen test for SARS-CoV-2 and influenza in a primary care population (RAPTOR-C19)

Fanshawe TR. et al, (2024), Clinical Microbiology and Infection

Lessons from the English primary care sentinel network's response to the COVID-19 pandemic

de Lusignan S. et al, (2024), The Lancet Infectious Diseases, 24, 14 - 16

Correction: Development and evaluation of rapid data-enabled access to routine clinical information to enhance early recruitment to the national clinical platform trial of COVID-19 community treatments (Trials, (2022), 23, 1, (62), 10.1186/s13063-021-05965-4)

Cake C. et al, (2023), Trials, 24

Informed consent in randomised controlled trials: further development and evaluation of the participatory and informed consent (PIC) measure

Wade J. et al, (2023), Trials, 24

A targeted approach to vaccine hesitancy

Leston M. et al, (2023), Oxford Open Immunology

COVID-19 vaccine effectiveness against hospitalisation and death of people in clinical risk groups during the Delta variant period: English primary care network cohort study

Whitaker HJ. et al, (2023), Journal of Infection, 87, 315 - 327

Enoxaparin for symptomatic COVID-19 managed in the ambulatory setting: An individual patient level analysis of the OVID and ETHIC trials

Barco S. et al, (2023), Thrombosis Research, 230, 27 - 32

The drivers of non-adherence to albuminuria testing guidelines and the clinical and economic impact of not identifying chronic kidney disease.

Groehl F. et al, (2023), Clin Nephrol, 100, 145 - 156

Platform adaptive trial of novel antivirals for early treatment of COVID-19 in the community (PANORAMIC): Protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease

Gbinigie O. et al, (2023), BMJ Open, 13

Predicting the risk of acute kidney injury in primary care:

Koshiaris C. et al, (2023), British Journal of General Practice, 73, E605 - E614

Load More

1
2
3
4
5
6
7
...
»